Company News

Polaris Group Announces Wayne Lin as New COO

SAN DIEGO, February 22, 2019 – Polaris Group announced today that Wayne Lin, MBA has been appointed as the Chief Operating Officer.

Mr. Lin brings over 20 years’ experience previously managing, as well as experience founding several startup companies and working as a venture capitalist. With his graduate work focused on corporate strategy and international management and his success licensing his patented software to companies including Amazon and Microsoft, Mr. Lin will be an instrumental team member as Polaris Group works to develop collaborative partnerships with other pharmaceutical companies for the clinical development of its lead anti-cancer compound, ADI-PEG 20.

About ADI‑PEG 20

ADI‑PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI‑PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI‑PEG 20.

About Polaris Group

Polaris Group specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. In addition to the ADI‑PEG 20 program, Polaris Group is developing other therapeutic agents, including a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

Scroll to Top
This site is registered on as a development site.